Jennerex grants Transgene exclusive rights to JX594
Jennerex Biotherapeutics Inc. (cancer) has granted immunotherapeutics company Transgene SA exclusive rights to develop and commercialize its Phase II solid tumor candidate JX594 in Europe, the Commonwealth of Independent States (CIS), and the Middle East.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.